On February 3, 2025, Soleil Boughton, Chief Legal Officer of Hims & Hers Health Inc, sold 4,153 shares of the company, as reported in the SEC Filing. Following this transaction, the insider now owns 161,497 shares of the company.
Hims & Hers Health Inc (HIMS, Financial) is a telehealth company that provides a range of health and wellness products and services. The company focuses on offering accessible and affordable healthcare solutions through its digital platform.
Over the past year, Soleil Boughton has sold a total of 618,520 shares and has not purchased any shares. The insider transaction history for Hims & Hers Health Inc indicates that there have been 2 insider buys and 120 insider sells over the same period.
On the day of the recent sale, shares of Hims & Hers Health Inc were trading at $35.3, giving the stock a market cap of $9.353 billion. The company's price-earnings ratio stands at 97.30, which is higher than the industry median of 17.27 and also higher than the company’s historical median price-earnings ratio.
With a trading price of $35.3 and a GF Value of $19.66, Hims & Hers Health Inc has a price-to-GF-Value ratio of 1.8, indicating that the stock is significantly overvalued based on its GF Value. The GF Value is an intrinsic value estimate developed by GuruFocus, calculated using historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor and future business performance estimates from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
